Hoffmann-La Roche: Observational study started recruiting, 1800 planned (Relapsing-Remitting Multiple Sclerosis)
Hoffmann-La Roche: Observational study started recruiting, 1800 planned (Relapsing-Remitting Multiple Sclerosis). Its enrollment of 1,800 is top-decile (96th percentile of 8,879 records). Dated 5 days ago, it is inside the fresh trigger window. Score 90/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 1,800 · 96th percentile of 8,879 ClinicalTrialStartPulse records · 22.5x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis |
| NCT ID | NCT07827586 |
| Phase | Observational |
| Status | recruiting |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention types | drug |
| Target enrollment | 1800 |
| Site countries | Czechia, Slovenia |
| Posted | 2026-09-18 |
| Planned start | 2026-09-23 |
| Event | Started recruiting |
| Event date | 2026-09-23 |
| Last update posted | 2026-10-30 |
| enrollment percentile | 96th of 8,879 (median 80, 22.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Hoffmann-La Roche
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Hoffmann-La Roche + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Hoffmann-La Roche and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Hoffmann-La Roche's enrollment: 96th percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
90 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- 1800 participants planned.
What is the ClinicalTrialStartPulse record for Hoffmann-La Roche?
Hoffmann-La Roche's Observational study (NCT07827586) in Relapsing-Remitting Multiple Sclerosis, first posted 2026-09-18: started recruiting (2026-09-23), in an update posted 2026-10-30.
How does Hoffmann-La Roche compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 1,800 is 22.5x the median of 80 across 8,879 records. It is fresh: dated 5 days ago, inside the window where early outreach matters most. Its Score of 90/100 puts it among the stronger signals in this feed.
Hoffmann-La Roche vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Hoffmann-La Roche | NONUS | 1,800 | 96th | 2026-10-30 |
| Janssen Pharmaceutica N.V., Belgium | NONUS | 1,314 | 95th | 2026-11-03 |
| Teva Branded Pharmaceutical Products R&D LLC | NONUS | 1,085 | 95th | 2026-11-03 |
| Janssen-Cilag International NV | NONUS | 135 | 68th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only
How to monitor Hoffmann-La Roche and peer observational records
Get new ClinicalTrialStartPulse records like Hoffmann-La Roche by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.